Citius pharmaceuticals to accelerate phase 3 mino-lok trial by expanding trial sites internationally

Additional sites to support trial completion by end of 2022 cranford, n.j. , may 6, 2022 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it has selected biorasi, llc ("biorasi"), a global clinical research organization (cro), to help expand the company's phase 3 mino-lok trial to additional sites outside the united states.
CTXR Ratings Summary
CTXR Quant Ranking